Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Raised by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 79.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,643 shares of the medical equipment provider's stock after purchasing an additional 2,935 shares during the period. J.W. Cole Advisors Inc.'s holdings in Intuitive Surgical were worth $3,290,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Intuitive Surgical during the fourth quarter worth $2,401,493,000. GAMMA Investing LLC boosted its position in shares of Intuitive Surgical by 54,010.7% during the first quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock worth $14,999,630,000 after buying an additional 3,022,979 shares during the period. Capital Research Global Investors boosted its position in Intuitive Surgical by 25.5% during the fourth quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider's stock valued at $1,764,904,000 after purchasing an additional 687,906 shares during the last quarter. Northern Trust Corp boosted its position in Intuitive Surgical by 15.8% during the fourth quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock valued at $1,889,126,000 after purchasing an additional 494,496 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after purchasing an additional 360,591 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other news, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $513.18, for a total value of $872,406.00. Following the transaction, the executive vice president owned 2,245 shares in the company, valued at $1,152,089.10. The trade was a 43.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 216 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares in the company, valued at $510,740.77. This represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,998 shares of company stock valued at $2,611,577. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ISRG. Evercore ISI increased their target price on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Robert W. Baird lowered their target price on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their price objective for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. Finally, Truist Financial lowered their price objective on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $592.86.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $518.62 on Monday. The company has a market capitalization of $185.88 billion, a price-to-earnings ratio of 76.04, a P/E/G ratio of 5.50 and a beta of 1.64. The business's 50-day moving average is $535.90 and its 200-day moving average is $536.29. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. The company had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the business earned $1.50 EPS. Analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.